Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006 Jun;55(6):842-7.
doi: 10.1136/gut.2005.076604. Epub 2005 Dec 23.

Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial

P Marteau  1 , M Lémann, P Seksik, D Laharie, J F Colombel, Y Bouhnik, G Cadiot, J C Soulé, A Bourreille, E Metman, E Lerebours, F Carbonnel, J L Dupas, M Veyrac, B Coffin, J Moreau, V Abitbol, S Blum-Sperisen, J Y Mary
Affiliations
Randomized Controlled Trial

Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial

P Marteau et al. Gut. 2006 Jun.

Abstract

Background and aims: Early endoscopic recurrence is frequent after intestinal resection for Crohn's disease. Bacteria are involved, and probiotics may modulate immune responses to the intestinal flora. Here we tested the probiotic strain Lactobacillus johnsonii LA1 in this setting.

Patients and methods: This was a randomised, double blind, placebo controlled study. Patients were eligible if they had undergone surgical resection of <1 m, removing all macroscopic lesions within the past 21 days. Patients were randomised to receive two packets per day of lyophilised LA1 (2 x 10(9) cfu) or placebo for six months; no other treatment was allowed. The primary endpoint was endoscopic recurrence at six months, with grade >1 in Rutgeerts' classification or an adapted classification for colonic lesions. Endoscopic score was the maximal grade of ileal and colonic lesions. Analyses were performed primarily on an intent to treat basis.

Results: Ninety eight patients were enrolled (48 in the LA1 group). At six months, endoscopic recurrence was observed in 30/47 patients (64%) in the placebo group and in 21/43 (49%) in the LA1 group (p = 0.15). Per protocol analysis confirmed this result. Endoscopic score distribution did not differ significantly between the LA1 and placebo groups. There were four clinical recurrences in the LA1 group and three in the placebo group.

Conclusion: L johnsonii LA1 (4 x 10(9) cfu/day) did not have a sufficient effect, if any, to prevent endoscopic recurrence of Crohn's disease.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rutgeerts P, Geboes K, Vantrappen G.et al Predictability of the postoperative course of Crohn's disease. Gastroenterology 199099956–963. - PubMed
    1. Marteau P, Lepage P, Mangin I.et al Gut flora and inflammatory bowel disease. Aliment Pharmacol Ther 200420(suppl 4)18–23. - PubMed
    1. Rutgeerts P, Hiele M, Geboes K.et al Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 19951081617–1621. - PubMed
    1. Rutgeerts P J, Van Assche G, Vermeire S.et al Ornidazole for prophylaxis of postoperative Crohn's disease recurrence of: a randomized double blind placebo controlled trial. Gastroenterology 2005128856–861. - PubMed
    1. Sartor R B. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 20041261620–1633. - PubMed

Publication types